Thermo Fisher Scientific shares reached a 52-week high of $671.69 on Sept. 24, 2026, lifting the company’s market capitalization to approximately $245.32 billion.
The test mark comes after the life-sciences instruments maker reported second-quarter results that surpassed Wall Street expectations, prompting an upgrade from UBS that moved its rating from Neutral to Buy.
For Q2 2026, adjusted earnings came in at $6.03 per share, ahead of the $5.72 analysts had forecast, while revenue of $11.99 billion topped the $11.71 billion estimate. Revenue rose 10% year over year, with organic growth accounting for roughly half of the gain.
Adjusted operating margin expanded to 22.8%, up from 21.9% a year earlier. The company said the improvement was broad-based across segments and reflected solid contributions from recent acquisitions.
Thermo Fisher also raised its full-year outlook, citing strengthened customer activity across end markets, particularly in pharmaceuticals and biotechnology.
UBS projects that organic revenue growth will return to a 5% to 6% pace by 2027, accompanied by operating margin expansion of at least 50 to 70 basis points and double-digit earnings-per-share growth.
The stock has climbed 45.51% over the past year and 36% over the last six months, extending its outperformance relative to the broader market.
Despite the rally, InvestingPro flagged the shares as overvalued relative to its fair-value estimate, placing Thermo Fisher on its “Most Overvalued” list and issuing 16 additional ProTips for the stock.
